JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

AstraZeneca PLC ADR

Abierto

74.43 0.01

Resumen

Variación precio

24h

Actual

Mínimo

74.27

Máximo

74.88

Métricas clave

By Trading Economics

Ingresos

1.7B

3.4B

Ventas

-1.3B

14B

P/B

Media del Sector

28.847

40.048

Rentabilidad por dividendo

2.16

Margen de beneficio

25.037

Empleados

94,300

EBITDA

610M

5B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+31.17% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.16%

2.45%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

9.4B

226B

Apertura anterior

74.42

Cierre anterior

74.43

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

AstraZeneca PLC ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 08:08 UTC

Ganancias

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 jul 2025, 06:46 UTC

Ganancias

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

1 ago 2025, 11:10 UTC

Acciones populares

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 jul 2025, 11:02 UTC

Ganancias

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 jul 2025, 11:02 UTC

Ganancias

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 jul 2025, 11:01 UTC

Ganancias

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 jul 2025, 11:00 UTC

Ganancias

AstraZeneca Results: H1 and Q2 2025

29 jul 2025, 08:00 UTC

Charlas de Mercado
Ganancias

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 jul 2025, 07:53 UTC

Charlas de Mercado
Ganancias

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 jul 2025, 07:26 UTC

Charlas de Mercado
Ganancias

AstraZeneca Shares Look Undervalued -- Market Talk

29 jul 2025, 06:03 UTC

Ganancias

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 jul 2025, 06:03 UTC

Ganancias

AstraZeneca 2Q Total Revenue $14.46B

29 jul 2025, 06:03 UTC

Ganancias

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 jul 2025, 06:03 UTC

Ganancias

AstraZeneca 2Q Core EPS $2.17

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 jul 2025, 06:02 UTC

Ganancias

AstraZeneca Backs 2025 View

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Rev $14.46B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Adj EPS $2.17

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Net Pft $2.45B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q Oper Pft $3.51B

29 jul 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 2Q EPS $1.57

28 jul 2025, 10:51 UTC

Charlas de Mercado

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22 jul 2025, 10:19 UTC

Charlas de Mercado

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22 jul 2025, 09:34 UTC

Acciones populares

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9 jul 2025, 10:59 UTC

Charlas de Mercado

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 jul 2025, 09:17 UTC

Acciones populares

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New -2-

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

Comparación entre iguales

Cambio de precio

AstraZeneca PLC ADR Esperado

Precio Objetivo

By TipRanks

31.17% repunte

Estimación a 12 meses

Media 97 USD  31.17%

Máximo 97 USD

Mínimo 97 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 69.55Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.